KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Petrylak, D. P. [1 ]
Li, B. [2 ]
Schloss, C. [2 ]
Fizazi, K. [3 ]
机构：
[1] Yale Univ, Smilow Canc Hosp, Med Oncol, New Haven, CT USA
[2] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[3] Gustave Roussy, Canc Med, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
891TiP
引用
收藏
页码：351 / 351
页数：1
相关论文
共 50 条
  • [1] Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921
    Petrylak, Daniel Peter
    Shore, Neal D.
    Bennamoun, Mostefa
    Ratta, Raffaele
    Piulats, Josep M.
    Li, Ben
    Schloss, Charles
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
    Romano, E.
    Sridhar, S. S.
    Kolinsky, M. P.
    Gravis, G.
    Mourey, L.
    Piulats, J. M.
    Berry, W. R.
    Gurney, H.
    Retz, M.
    Appleman, L. J.
    Boegemann, M.
    de Bono, J. S.
    Joshua, A. M.
    Emmenegger, U.
    Conter, H. J.
    Laguerre, B.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S512 - S513
  • [3] Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony
    Linch, Mark David
    Kolinsky, Michael
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Pembrolizumab plus docetaxel and prednisone for enzalutamide- or abiraterone acetate-pretreated patients with metastatic castration-resistant prostate cancer: phase 3 KEYNOTE-921 study
    Shore, Neal
    Petrylak, Daniel
    Bennamoun, Mostefa
    Ratta, Raffaele
    Piulats, Josep
    Li, Ben
    Schloss, Charles
    Fizazi, Karim
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [5] KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer
    Petrylak, Daniel P.
    Ratta, Raffaele
    Gafanov, Rustem
    Facchini, Gaetano
    Piulats, Josep M.
    Kramer, Gero
    Flaig, Thomas W.
    Chandana, Sreenivasa R.
    Li, Ben
    Burgents, Joseph
    Fizazi, Karim
    FUTURE ONCOLOGY, 2021, 17 (25) : 3291 - 3299
  • [6] Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
    Sridhar, Srikala S.
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Rodriguez, Jose Maria M. Piulats
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
    Mourey, L.
    Conter, H. J.
    Shore, N.
    Berry, W. R.
    Fong, P. C.
    Piulats, J. M.
    Appleman, L. J.
    Todenhoefer, T.
    Gravis, G.
    Laguerre, B.
    Gurney, H.
    Retz, M.
    Romano, E.
    de Bono, J. S.
    Kam, A. E.
    Emmenegger, U.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S516 - S517
  • [8] Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel P.
    Ratta, Raffaele
    Matsubara, Nobuaki
    Korbenfeld, Ernesto Pablo
    Gafanov, Rustem
    Mourey, Loic
    Fer, Tilman Todenho Spacing Diaeresis
    Gurney, Howard
    Kramer, Gero
    Bergman, Andre M.
    Zalewski, Pawel
    De Santis, Maria
    Armstrong, Andrew J.
    Gerritsen, Winald R.
    Pachynski, Russell Kent
    Saretsky, Todd L.
    Ghate, Sameer R.
    Li, Xin Tong
    Schloss, Charles
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [9] Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony
    Gurney, Howard
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Piulats, Josep M.
    Sridhar, Srikala S.
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345